Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8402080 | 1.00 | ATM (0.36) | ATML3MBTL1KMT2AAOC3CYP2D6 | |
| SCHEMBL8406168 | 1.00 | ATM (0.36) | ATML3MBTL1KMT2AAOC3CYP2D6 | |
| SCHEMBL8993410 | 0.91 | PTGS2 (0.37) | — | |
| SCHEMBL8993613 | 0.91 | PTGS2 (0.37) | — | |
| SCHEMBL8993490 | 0.85 | FFAR2 (0.35) | KMT2ACYP2D6LMNAMAPK1CYP3A4 | |
| SCHEMBL9116402 | 0.85 | FFAR2 (0.35) | KMT2ACYP2D6LMNAMAPK1CYP3A4 | |
| SCHEMBL8993485 | 0.85 | FFAR2 (0.35) | KMT2ACYP2D6LMNAMAPK1CYP3A4 | |
| SCHEMBL21437443 | 0.83 | APLNR (0.39) | — | |
| SCHEMBL2337690 | 0.83 | APLNR (0.31) | — | |
| SCHEMBL1537047 | 0.82 | NPSR1 (0.39) | L3MBTL1KMT2ACYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227839-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-5977374-A | 5-(4-hydroxy-OR 4-acetoxy-benzyl)-3- triphenylmethylthiazolidine-2,4-dione and method for producing same | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5635534-A | 1-PHENYL-2-(2-PHENYLOXY OR THIO)-1-METHYLETHYL)AMINOETHANOL DERIVATIVES; ALDOSE REDUCTASE INHIBITORS; NONTOXIC; ANTIDIABETIC,-OBESITY,-LIPEMIC AND HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-06-03 | — | — | US | disclosed |
| US-5576340-A | Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0543662-B1 | Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses | SANKYO CO (JP) | 1996-09-18 | — | — | EP | disclosed |
| EP-0543662-A2 | Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 1993-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227839-A1 | Kinase Inhibitors | ABL1, MAP3K20, MAP3K19 | ATM 395/4885L3MBTL1 2220/4885KMT2A 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.